Trial Profile

Research evaluation to study individuals who show thromboxane or P2Y12 receptor resistance

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eptifibatide (Primary) ; Heparin
Indications Coronary artery disease; Embolism and thrombosis
Focus Pharmacodynamics

Most Recent Events

01 Feb 2013 Planned number of patients changed from 600 to 1200 as reported by ClinicalTrials.gov.
19 Jul 2007 Status changed from recruiting to discontinued. Sponsor support withdrawn.
21 Jul 2006 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com